Understanding ALK Fusion in Lung Cancer

ALK (Anaplastic Lymphoma Kinase) fusion mutations occur in approximately 3-5% of non-small cell lung cancers (NSCLC). These patients have access to highly targeted therapies that significantly improve outcomes compared to traditional chemotherapy.

3-5%

of NSCLC patients

ALK Rearrangement

Prognostic biomarker

3 FDA-approved

ALK inhibitors (1st-gen)

Multiple trials

Testing newer combinations

ALK Fusion Variants

The most common ALK fusion partner is EML4 (echinoderm microtubule-associated protein-like 4), though other fusion partners exist:

EML4-ALK (90% of cases)

Most common ALK fusion variant, responsive to most ALK inhibitors.

Other Partners (~10%)

KIF5B-ALK, TFG-ALK, and other rare fusion partners may show variable drug sensitivity.

Variant Classification

Different EML4-ALK variants have different kinetic properties and drug sensitivities.

Treatment Pathways for ALK+ NSCLC

First-Line Therapy

Alectinib (Alecensa) - Brain penetration, preferred choice
Brigatinib (Alunbrig) - Dual ALK/ROS1 inhibitor
Lorlatinib (Lorbrena) - Second-generation, CNS-active
Crizotinib for patients unable to tolerate newer agents

Post-First-Line ALK Inhibitor

Lorlatinib after alectinib/brigatinib
Switching between ALK inhibitors based on resistance patterns
Clinical trials testing next-generation ALK inhibitors
Combination strategies with chemotherapy

Resistance Management

Identifying ALK resistance mutations
Brain metastases management (high-dose ALK inhibitors, radiation)
Trials for ALK-resistant mutations
Combination immunotherapy approaches

Emerging Options

Third-generation ALK inhibitors in development
Bispecific antibodies targeting ALK
Combinations with immunotherapy or chemotherapy
Trials addressing specific resistance mechanisms

Frequently Asked Questions

What is an ALK fusion and how is it detected? +

An ALK fusion is a rearrangement where the ALK gene fuses with another gene (most commonly EML4). This creates an abnormal protein that drives cancer growth. Detection methods include FISH (fluorescence in situ hybridization), immunohistochemistry (IHC), and next-generation sequencing (NGS). Your oncologist can order these tests as part of your lung cancer diagnosis.

Why are ALK inhibitors different from chemotherapy? +

ALK inhibitors are targeted therapies that specifically block the abnormal ALK protein, whereas chemotherapy damages cancer cells non-specifically. Because ALK inhibitors target the specific driver mutation, they typically have better effectiveness and fewer side effects compared to traditional chemotherapy for ALK+ patients.

Can ALK inhibitors penetrate the brain? +

Yes, some ALK inhibitors have better brain penetration than others. Alectinib and lorlatinib, for example, were designed to cross the blood-brain barrier effectively, making them better options for patients with brain metastases. This is an important consideration in treatment selection.

What happens when I become resistant to ALK therapy? +

Resistance can develop through secondary mutations in the ALK gene or other mechanisms. When this happens, switching to a different ALK inhibitor (e.g., from crizotinib to alectinib to lorlatinib) is a common approach. Clinical trials are also exploring new combination strategies and next-generation inhibitors to overcome resistance.

Are there clinical trials for ALK+ lung cancer? +

Yes, there are ongoing clinical trials testing new ALK inhibitors, combination therapies, and strategies to overcome resistance. Many trials are actively recruiting. Use our search tool below to find trials that match your specific ALK status and treatment history.

ALK Fusion Lung Cancer